Reosil may be available in the countries listed below.
Bromhexine hydrochloride (a derivative of Bromhexine) is reported as an ingredient of Reosil in the following countries:
International Drug Name Search
Domperidon AbZ may be available in the countries listed below.
Domperidone is reported as an ingredient of Domperidon AbZ in the following countries:
International Drug Name Search
Famtac may be available in the countries listed below.
Famotidine is reported as an ingredient of Famtac in the following countries:
International Drug Name Search
Urocin may be available in the countries listed below.
Mitomycin is reported as an ingredient of Urocin in the following countries:
International Drug Name Search
Elmendos may be available in the countries listed below.
Lamotrigine is reported as an ingredient of Elmendos in the following countries:
International Drug Name Search
In the US, Pramosone (hydrocortisone/pramoxine topical) is a member of the drug class anorectal preparations and is used to treat Dermatitis, Dermatological Disorders, Hemorrhoids and Psoriasis.
US matches:
Hydrocortisone 21-acetate (a derivative of Hydrocortisone) is reported as an ingredient of Pramosone in the following countries:
Pramocaine hydrochloride (a derivative of Pramocaine) is reported as an ingredient of Pramosone in the following countries:
International Drug Name Search
Nicotibina may be available in the countries listed below.
Isoniazid is reported as an ingredient of Nicotibina in the following countries:
International Drug Name Search
Treating high blood pressure and chronic stable angina (chest pain). It may be used alone or in combination with other medicines. It may also be used for other conditions as determined by your doctor.
Diltiazem 24-Hour Extended-Release Beads Tablets are a calcium channel blocker. It works by relaxing (dilating) your blood vessels, lowering blood pressure, and decreasing heart rate, which lowers the workload of the heart. It also dilates coronary arteries, which increases blood flow to the heart.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Diltiazem 24-Hour Extended-Release Beads Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Diltiazem 24-Hour Extended-Release Beads Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Diltiazem 24-Hour Extended-Release Beads Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Diltiazem 24-Hour Extended-Release Beads Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Diltiazem 24-Hour Extended-Release Beads Tablets.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; dizziness; facial flushing; headache; lightheadedness; tiredness; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); chest pain; fainting; fast, slow, or irregular heartbeat; fever, chills, or sore throat; hallucinations; mental or mood changes; personality changes; reddened, blistered, or swollen skin; severe or persistent dizziness, lightheadedness, nausea, or vomiting; shortness of breath; sudden weight gain; swelling of the feet, ankles, or hands; symptoms of liver problems (eg, dark urine, pale stools, yellowing of the skin or eyes); tender, bleeding, or swollen gums; unusual bleeding or bruising; unusual or persistent tiredness or weakness; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Diltiazem side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; difficulty breathing, especially when lying down; dizziness; drowsiness; fainting; lightheadedness, especially when standing; loss of consciousness; nausea; nervousness; slurred speech; unusual weakness; very slow heart rate.
Store Diltiazem 24-Hour Extended-Release Beads Tablets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Diltiazem 24-Hour Extended-Release Beads Tablets out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Diltiazem 24-Hour Extended-Release Beads Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Infufer may be available in the countries listed below.
Iron Dextran is reported as an ingredient of Infufer in the following countries:
International Drug Name Search
Molsidomine Winthrop may be available in the countries listed below.
Molsidomine is reported as an ingredient of Molsidomine Winthrop in the following countries:
International Drug Name Search
Norethisterone is reported as an ingredient of Nor-Q.D. in the following countries:
International Drug Name Search
Dolflam may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Dolflam in the following countries:
International Drug Name Search
Doctodermis may be available in the countries listed below.
Biotin is reported as an ingredient of Doctodermis in the following countries:
Triclosan is reported as an ingredient of Doctodermis in the following countries:
International Drug Name Search
Comsporin may be available in the countries listed below.
Cefixime is reported as an ingredient of Comsporin in the following countries:
International Drug Name Search
Colaspase may be available in the countries listed below.
Colaspase (BAN) is known as Asparaginase in the US.
International Drug Name Search
Glossary
| BAN | British Approved Name |
Bromfenac Sodium may be available in the countries listed below.
Bromfenac Sodium (USAN) is known as Bromfenac in the US.
International Drug Name Search
Glossary
| USAN | United States Adopted Name |
Acébutolol Qualimed may be available in the countries listed below.
Acebutolol hydrochloride (a derivative of Acebutolol) is reported as an ingredient of Acébutolol Qualimed in the following countries:
International Drug Name Search
Preventing certain types of rotavirus infection in infants and children.
Rotavirus Oral Vaccine Live is a live viral vaccine for rotavirus. Rotavirus Oral Vaccine Live works by helping the immune system to protect against rotavirus.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Rotavirus Oral Vaccine Live. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Rotavirus Oral Vaccine Live. Tell your health care provider if the patient is taking any other medicines, especially any of the following:
Ask your health care provider if Rotavirus Oral Vaccine Live may interact with other medicines that the patient takes. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Rotavirus Oral Vaccine Live as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Rotavirus Oral Vaccine Live.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Mild fever, diarrhea, or vomiting; runny nose; sore throat.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in the stool; change in bowel movements; ear pain; high fever; red eyes or mouth; severe or persistent stomach pain, diarrhea, or vomiting; swelling of the hands or feet; swollen glands; wheezing or coughing.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Rotavirus Oral Vaccine Live is usually handled and stored by a health care provider. If you are using Rotavirus Oral Vaccine Live at home, store Rotavirus Oral Vaccine Live as directed by your pharmacist or health care provider. Protect from light. Keep Rotavirus Oral Vaccine Live out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Rotavirus Oral Vaccine Live. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Metrix may be available in the countries listed below.
Glimepiride is reported as an ingredient of Metrix in the following countries:
International Drug Name Search
Sparx may be available in the countries listed below.
Sparfloxacin is reported as an ingredient of Sparx in the following countries:
International Drug Name Search
Equipax may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Gabapentin is reported as an ingredient of Equipax in the following countries:
International Drug Name Search
Clotrimaderm may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Clotrimaderm in the following countries:
International Drug Name Search
Pan-Heparin sodium may be available in the countries listed below.
Heparin sodium salt (a derivative of Heparin) is reported as an ingredient of Pan-Heparin sodium in the following countries:
International Drug Name Search
Anginin may be available in the countries listed below.
Pyricarbate is reported as an ingredient of Anginin in the following countries:
International Drug Name Search
Streptomicina may be available in the countries listed below.
Streptomicina (DCIT) is known as Streptomycin in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Suplentin may be available in the countries listed below.
Amoxicillin sodium salt (a derivative of Amoxicillin) is reported as an ingredient of Suplentin in the following countries:
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Suplentin in the following countries:
Clavulanic Acid is reported as an ingredient of Suplentin in the following countries:
Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Suplentin in the following countries:
International Drug Name Search
Pritamox may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Pritamox in the following countries:
International Drug Name Search
Tercian may be available in the countries listed below.
Cyamemazine is reported as an ingredient of Tercian in the following countries:
Cyamemazine tartrate (a derivative of Cyamemazine) is reported as an ingredient of Tercian in the following countries:
International Drug Name Search
Betamatic may be available in the countries listed below.
Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Betamatic in the following countries:
International Drug Name Search
In the US, RMS (morphine systemic) is a member of the drug class narcotic analgesics and is used to treat Pain.
US matches:
Morphine sulphate pentahydrate (a derivative of Morphine) is reported as an ingredient of RMS in the following countries:
International Drug Name Search
Amlodipine Acion may be available in the countries listed below.
Amlodipine maleate (a derivative of Amlodipine) is reported as an ingredient of Amlodipine Acion in the following countries:
International Drug Name Search
Atorva may be available in the countries listed below.
Atorvastatin calcium (a derivative of Atorvastatin) is reported as an ingredient of Atorva in the following countries:
International Drug Name Search
In the US, Gemfibrozil (gemfibrozil systemic) is a member of the drug class fibric acid derivatives and is used to treat High Cholesterol, Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb - Elevated LDL VLDL, Hyperlipoproteinemia Type IV - Elevated VLDL and Hyperlipoproteinemia Type V - Elevated Chylomicrons VLDL.
US matches:
Rec.INN
C10AB04
0025812-30-0
C15-H22-O3
250
Antilipemic agent, fibrate
Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Vesalion may be available in the countries listed below.
Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Vesalion in the following countries:
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Vesalion in the following countries:
International Drug Name Search
Blocacid may be available in the countries listed below.
Famotidine is reported as an ingredient of Blocacid in the following countries:
International Drug Name Search
Metoclopramide ratiopharm may be available in the countries listed below.
Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Metoclopramide ratiopharm in the following countries:
International Drug Name Search
Cefalexine Kombivet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Cefalexine Kombivet in the following countries:
International Drug Name Search
Welldorm may be available in the countries listed below.
Chloral Hydrate is reported as an ingredient of Welldorm in the following countries:
Chloral Hydrate compound with betaine (a derivative of Chloral Hydrate) is reported as an ingredient of Welldorm in the following countries:
International Drug Name Search
Lacrimin may be available in the countries listed below.
Oxybuprocaine hydrochloride (a derivative of Oxybuprocaine) is reported as an ingredient of Lacrimin in the following countries:
International Drug Name Search
Amoxapen may be available in the countries listed below.
Amoxicillin is reported as an ingredient of Amoxapen in the following countries:
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxapen in the following countries:
International Drug Name Search
Mafena may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Mafena in the following countries:
International Drug Name Search
Feprorex may be available in the countries listed below.
Fenproporex hydrochloride (a derivative of Fenproporex) is reported as an ingredient of Feprorex in the following countries:
International Drug Name Search
Class: Parasympathomimetic (Cholinergic) Agents
VA Class: AU300
Chemical Name: 2,3-Dihydro-5,6-dimethoxy-2-[(1-(phenylmethyl)-4-piperidinyl)methyl]-1H-inden-1-one
Molecular Formula: C24H29NO3
CAS Number: 120014-06-4
Brands: Aricept
Centrally active, reversible acetylcholinesterase inhibitor.1 2 3 7
Palliative treatment of mild to moderate dementia of the Alzheimer’s type (Alzheimer’s disease, presenile or senile dementia).1 2 3 4 6 15
Comparative studies have not been performed to date, but donepezil does not share the hepatotoxic potential of tacrine and may be preferable to tacrine as a first-line treatment because it can be administered once daily and does not require regular monitoring of liver function.5 6
Administer conventional or orally disintegrating tablets orally once daily, usually at bedtime.1 2
Administer with or without food.1 2
Orally disintegrating tablets: Place on tongue and allow to dissolve; follow with water.1
Donepezil hydrochloride orally disintegrating and conventional film-coated tablets are bioequivalent.1
Available as donepezil hydrochloride; dosage expressed in terms of the salt.1
Initially, 5 mg daily.1 6 11
Some data suggest the possibility of additional benefit with higher (10 mg daily) dosage in some patients;1 2 6 12 however, additional benefit with the 10-mg dosage has not been demonstrated in controlled clinical studies.1 2 12 Adverse cholinergic effects are more likely with the 10-mg dosage.1 2
Daily administration of 10 mg should not be considered until patient has received 5 mg daily for 4–6 weeks, since occurrence of adverse effects may be influenced by the rate of increase in dosage.1 2 11
No specific recommendation for dosage adjustment.1
Known hypersensitivity to donepezil or piperidine derivatives or any ingredient in the formulation.1
Potential for exaggerated succinylcholine-type muscle relaxation during anesthesia.1
Cholinesterase inhibitors may produce bradycardia or heart block via vagotonic effects on the sinoatrial or AV nodes.1 May occur in patients with or without known cardiac conduction abnormalities.1 14 Syncope reported in patients receiving donepezil.1
Possible diarrhea, nausea, and vomiting, particularly at dosage of 10 mg daily.1
Potential for increased gastric acid secretion.1
Carefully monitor patients, especially those at increased risk for developing ulcers (e.g., those with history of peptic ulcer disease, those receiving concomitant NSAIA therapy), for symptoms of active or occult GI bleeding.1
Although not reported in clinical studies with donepezil, cholinomimetic agents may cause bladder outflow obstruction.1 14
Use with caution in patients with a history of asthma or obstructive pulmonary disease.1
Cholinomimetic agents may have the potential to cause generalized seizures; however, seizures also may be a manifestation of Alzheimer’s disease.1
Category C.1
Not known whether donepezil is distributed into milk.1 Not indicated for use in nursing women.1
Safety and efficacy not established.1
Dementia of the Alzheimer's type occurs principally in patients >55 years of age.1 The mean age of patients receiving donepezil in clinical studies was 73 years of age.1 No substantial differences in most adverse effects in patients ≥65 years of age relative to those <65 years of age.1
Nausea, diarrhea, insomnia, vomiting, muscle cramp, fatigue, anorexia.1
Metabolized by CYP3A4 and CYP2D6.1 Unlikely to cause clinically important induction or inhibition of CYP3A4 or CYP2D6; not known whether donepezil has any enzyme-induction potential.1
Pharmacokinetic interactions unlikely with drugs highly bound to plasma proteins.1
Unlikely to alter clearance of drugs metabolized by CYP3A4 or CYP2D6.1
Possible pharmacokinetic interaction (altered plasma donepezil concentrations) with CYP2D6 or CYP3A4 inducers or inhibitors.1
Drug | Interaction | Comments |
|---|---|---|
Anticholinergic agents | Possible interference with activity of anticholinergic agents1 | |
Carbamazepine | Possible induction of donepezil metabolism1 | |
Cholinergic agonists (e.g., bethanecol) | Synergistic effect1 | |
Cholinesterase inhibitors | Synergistic effect1 | |
Cimetidine | No clinically important effects observed on pharmacokinetics of either drug with concomitant use1 | |
Dexamethasone | Possible induction of donepezil metabolism1 | |
Digoxin | No clinically important effects observed on pharmacokinetics of either drug with concomitant use1 | |
Furosemide | Pharmacokinetic interactions (including protein binding interactions) unlikely1 | |
Ketoconazole | Plasma donepezil concentrations increased by 36% with concomitant use; no change in ketoconazole pharmacokinetics1 Inhibition of donepezil metabolism observed in vitro1 | Clinical importance not known1 |
Neuromuscular blocking agents (e.g., succinylcholine) | Exaggerated muscle relaxation1 | |
Phenobarbital | Possible induction of donepezil metabolism1 | |
Phenytoin | Possible induction of donepezil metabolism1 | |
Quinidine | Inhibition of donepezil metabolism in vitro1 | Clinical importance not known1 |
Rifampin | Possible induction of donepezil metabolism1 | |
Theophylline | Pharmacokinetic interaction unlikely1 | |
Warfarin | Pharmacokinetic interactions (including protein binding interactions) unlikely1 |
Relative oral bioavailability is 100%.1
Orally disintegrating and conventional film-coated tablets are bioequivalent.1
Food does not affect rate or extent of absorption when administered as conventional film-coated tablets.1 Effect of food on donepezil absorption after administration as orally disintegrating tablets has not been studied, but any effects are expected to be minimal; orally disintegrating tablets may be taken without regard to meals.1
Approximately 96% (mainly albumin [75%] and alpha1-acid glycoprotein [21%]).1
Extensively metabolized to 4 major metabolites (2 known to be active) and a number of minor metabolites.1 Is metabolized by CYP2D6 and CYP3A4 and undergoes glucuronidation.1
Eliminated in urine and feces (57 and 15%, respectively, over 10 days, with 28% still unrecovered; about 17% of the dose recovered in urine as unchanged drug).1
About 70 hours.1
In patients with stable alcoholic cirrhosis, clearance appears to be reduced by about 20%.1
In patients with moderate to severe renal impairment (Clcr <22 mL/minute per 1.73 m2), clearance appears to be similar to that in healthy individuals.1
15–30°C.1
Precise mechanism(s) of action in patients with dementia of the Alzheimer’s type not fully elucidated.1 Binds reversibly with and inactivates cholinesterases (e.g., acetylcholinesterase), thus inhibiting hydrolysis of acetylcholine1 3 6 7 10 11 12 15 and resulting in increased acetylcholine concentrations at cholinergic synapses.1 6
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 6
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets, film-coated | 5 mg | Aricept | Eisai, (also promoted by Pfizer) |
10 mg | Aricept | Eisai, (also promoted by Pfizer) | ||
Tablets, orally disintegrating | 5 mg | Aricept ODT | Eisai, (also promoted by Pfizer) | |
10 mg | Aricept ODT | Eisai, (also promoted by Pfizer) |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Aricept 10MG Tablets (EISAI): 30/$275.98 or 90/$739.94
Aricept 5MG Tablets (EISAI): 30/$276 or 90/$745.98
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2006. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Eisai Inc. Aricept (donepezil hydrochloride) tablets and orally disintegrating tablets prescribing information. Teaneck, NJ; 2005 Mar.
2. Eisai Inc. Aricept product monograph. Teaneck, NJ; 1997 Jan.
3. Bryson HM, Benfield P. Donepezil. Drugs Aging. 1997; 10:234-9. [PubMed 9108896]
4. Mohs RC. Donepezil: a viewpoint. Drugs Aging. 1997; 10:240.
5. Whitehouse PJ. Donepezil: a viewpoint. Drugs Aging. 1997; 10:240-1.
6. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry. 1997; 154:1-39.
7. Caspi A. Donepezil, a novel therapy for Alzheimer’s disease. P&T. 1997; 22(Feb):70-4.
8. Rogers SL, Doody R, Mohs R et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer’s disease: results of a 30-week phase III trial. Neurology. 1996; 46:A217. [PubMed 8559362]
9. Doraiswamy PM. Current cholinergic therapy for symptoms of Alzheimer’s disease. Primary Psychiatry. 1996; Nov:56-68.
10. Brufani M, Filocamo L, Lappa S et al. New acetylcholinesterase inhibitors. Drugs Fut. 1997; 22:397-410.
11. Anonymous. Donepezil (Aricept) for Alzheimer’s disease. Med Lett Drugs Ther. 1997; 39:53-4. [PubMed 9187642]
12. Rho JP, Lipson LG. Focus on donepezil: a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Formulary. 1997; 32:677-84.
13. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996; 7(Nov-Dec):293-303. [PubMed 8915035]
14. Eisai Inc, Teaneck, NJ: Personal communication.
15. Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA. 1997; 278:1363-71. [IDIS 393115] [PubMed 9343469]
16. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001; 56:1154-66. [IDIS 463599] [PubMed 11342679]
Plusvent Accuhaler may be available in the countries listed below.
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Plusvent Accuhaler in the following countries:
Salmeterol xinafoate (a derivative of Salmeterol) is reported as an ingredient of Plusvent Accuhaler in the following countries:
International Drug Name Search
Periodil may be available in the countries listed below.
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Periodil in the following countries:
International Drug Name Search
Flogoral may be available in the countries listed below.
Benzydamine hydrochloride (a derivative of Benzydamine) is reported as an ingredient of Flogoral in the following countries:
International Drug Name Search
Metoprolol Teva may be available in the countries listed below.
Metoprolol tartrate (a derivative of Metoprolol) is reported as an ingredient of Metoprolol Teva in the following countries:
International Drug Name Search
Cyanocobalaminum-Darnitsa may be available in the countries listed below.
Cyanocobalamin is reported as an ingredient of Cyanocobalaminum-Darnitsa in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Ophthaine is a member of the drug class ophthalmic anesthetics.
Proxymetacaine hydrochloride (a derivative of Proxymetacaine) is reported as an ingredient of Ophthaine in the following countries:
International Drug Name Search
Lotim may be available in the countries listed below.
Losartan is reported as an ingredient of Lotim in the following countries:
International Drug Name Search
Thalomid is a brand name of thalidomide, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Thalomid available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Thalomid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
